News | Pacemakers | May 12, 2023

Biotronic Receives CE Approval for the World’s First Pacemaker and CRT-P Family Approved for Left Bundle Branch Pacing

The Amvia family enables physiological pacing and workflow optimization to help physicians deliver exceptional patient-centric care with less effort

The Amvia family enables physiological pacing and workflow optimization to help physicians deliver exceptional patient-centric care with less effort.

The Amvia Pacemaker and CRT-P Family 


May 12, 2023 — Biotronik, a leading global medical technology company with 60 years of experience in developing trusted cardiovascular and endovascular solutions, announced today the latest addition to its cardiac rhythm management portfolio. "We are excited to have received CE mark for our newest technology – the world’s first pacemakers and CRT-Ps approved for left bundle branch pacing. Amvia Sky and Amvia Edge represent cutting-edge innovation and incorporate the latest cardiology trends," says Dr. Andreas Hecker, President CRM/EP at Biotronik. In 1963, Biotronik introduced the first German implantable pacemaker and is still driven today by this innovative spirit as it continues to advance the cardiovascular market. 

Left bundle branch area pacing (LBBAP) is a relatively new, more physiologic approach in cardiac pacing. Previous studies pointed out that physiologic pacing could maintain or even improve cardiac function and improve long-term clinical outcomes compared to conventional right ventricular pacing.5,6,7 In a recent multi-center study, Prof. Dr. Jan De Pooter, Cardiology and Electrophysiology at the University Hospital Ghent claims that "LBBAP using Biotronik conduction system tools is a safe and reliable treatment option. It is associated with high implant success, low pacing thresholds and high safety profile."8 The Amvia family now ties in perfectly with these tools. 

Alongside the broad range of choices for physiologic pacing, the Amvia family also offers new tools that automate and streamline many tasks during implantation, in-office follow-ups and remote monitoring. Furthermore, MRI Guard 24/7, the next-generation MRI access addition, provides an automatic MRI mode switch for easy examinations without pre- and post-scan programming appointments9,10 – for the benefit of both care teams and patients. Prof. Dr. Justin Mariani, Associate Professor, The Alfred Hospital Heart Centre, Melbourne, Australia, is leading the first in-human study of the Amvia system called BIO|CONCEPT Amvia. "The advantages of the Amvia family look very promising. The systems include several physiologic pacing and time-saving functions that will improve clinical workflows and patient care," says Prof. Mariani. Final results of the study are expected later this year. 

Biotronik 's latest innovative family of pacemaker and CRT-P systems embodies the company's dedication to patient-centric technology for better patient care and workflow simplification to address healthcare provider needs. With 60 years of experience, Biotronik continues its mission to perfectly match technology with the human body in order to deliver better patient outcomes. 

For more information: www.biotronik.com 

 

References: 

*1.    Biotronik Amvia Sky technical manual, Medtronic Azure XT DR MRI SureScan manual; Boston Scientific Accolade MRI technical manual; Abbott Assurity MRI user’s manual; MicroPort Alizea implant manual. 

2.    Watanabe E, Yamazaki F, Goto T, et al. Remote management of pacemaker patients with biennial in-clinic evaluation: continuous Home Monitoring in the Japanese At-Home study: A randomized clinical trial. Circ Arrhythm Electrophysiol. 2020 May;13(5):e007734. doi: 10.1161/CIRCEP.119.007734.  

3.    Mabo P, Victor F, Bazin P, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial). Eur Heart J. 2012; 33(9): 1105-1111. 

4.    Garcia-Fernández FJ, Asensi JO, Romero R, et al. Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE). Eur Heart J. 2019; 40(23): 1837–1846. 

5.    Li Y, Yan L, Dai Y, et al. Feasibility and efficacy of left bundle branch area pacing in patients indicated for cardiac resynchronization therapy. Europace. 2020; 22(Suppl_2): ii54-ii60.

6.    Li X, Zhang J, Qiu C, et al. Clinical Outcomes in Patients With Left Bundle Branch Area Pacing vs. Right Ventricular Pacing for Atrioventricular Block. Front Cardiovasc Med. 2021; 8:685253. 

7.    Liu Q, Yang J, Bolun Z, et al. Comparison of cardiac function between left bundle branch pacing and right ventricular outflow tract septal pacing in the short-term: A registered controlled clinical trial. Int J Cardiol. 2021; 322: 70-76. 

8.    De Pooter, Jan; Ozpak, Emine ; Calle, Simon ; Peytchev, Peter ; Heggermont, Ward; Marchandise, Sebastien; Provenier, Frank, Francois, Bert; Anne, Wim; Pollet, Peter, Barbaud, Cynthia, Gillis, Kris, Timermans, Frank; Van Heuverswyn, Frederic; Tung, Roderick, Wauters, Aurelien; lePolain de Warous, Jean-Benoit (2022): Initial experience of the left bundle branch area pacing using stylet-driven pacing leads: A multicentre study. In J. Cardiovasc Electrophysiol (7), pp.1540-1549. DOI:10.1111/jce.15558. 

9.    Data on file.

10.  Mullane S, Michaelis K, Henrickson C, et al. Utilization and programming of an automatic MRI recognition feature for cardiac rhythm management devices. Heart Rhythm. O2. 2021; 2: 132–137.


Related Content

News | Heart Failure

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

Home February 22, 2024
Home
News | Heart Failure

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

Home February 15, 2024
Home
News | Heart Failure

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully ...

Home February 12, 2024
Home
News | Heart Failure

January 30, 2024 — Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single ...

Home January 30, 2024
Home
News | Heart Failure

January 23, 2024 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home January 23, 2024
Home
News | Heart Failure

January 16, 2024 — Cardiac Dimensions, a leader in the development of innovative and minimally invasive treatment ...

Home January 16, 2024
Home
News | Heart Failure

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 30, 2023
Home
News | Heart Failure

November 30, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home November 30, 2023
Home
News | Heart Failure

November 16, 2023 — Mount Sinai’s Cardiovascular Research Institute is sending bioengineered human heart muscle cells ...

Home November 16, 2023
Home
News | Heart Failure

November 16, 2023 — A smartphone app using artificial intelligence technology to detect changes in the voice of a person ...

Home November 16, 2023
Home
Subscribe Now